XML 23 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 32,443 $ 39,067
Short-term investments 251,628 197,959
Accounts receivable, net 1,855 2,229
Inventory 12,872 13,452
Other current assets 5,972 5,175
Total current assets 304,770 257,882
Restricted cash 25,000 25,000
Property and equipment, net 72,968 66,974
Goodwill 76,501 76,501
Other assets 7,774 8,170
Total assets 487,013 434,527
Current liabilities:    
Accounts payable 3,064 9,115
Accrued compensation 9,427 14,254
Accrued expenses 6,821 6,243
Accrued clinical trial expenses 13,726 16,905
Interest payable 3,167 6,917
Deferred revenue, current portion 23,542 23,664
Liability related to the sales of future royalties, current portion   7,000
Other current liabilities 19,566 14,123
Total current liabilities 79,313 98,221
Senior secured notes 125,000 125,000
Capital lease obligations, less current portion 7,050 8,049
Liability related to receipt of refundable milestone payment 70,000 70,000
Liability related to sale of future royalties, less current portion 121,134 121,520
Deferred revenue, less current portion 76,549 82,384
Other long-term liabilities 17,776 19,256
Total liabilities 496,822 524,430
Commitments and contingencies      
Stockholders' equity (deficit):    
Preferred stock, $0.0001 par value, 10,000 shares authorized, no shares designated, issued or outstanding at March 31, 2014 or December 31, 2013, respectively      
Common stock, $0.0001 par value; 300,000 authorized; 126,936 shares and 116,494 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively 12 11
Capital in excess of par value 1,769,713 1,643,660
Accumulated other comprehensive loss (940) (1,181)
Accumulated deficit (1,778,594) (1,732,393)
Total stockholders' equity (deficit) (9,809) (89,903)
Total liabilities and stockholders' equity (deficit) $ 487,013 $ 434,527